Compositions and methods for treating emphysema

A composition and alveolar technology, applied in drug combination, drug delivery, pharmaceutical formulation, etc., can solve problems such as impaired quality of life, increased frequency of hospitalization, and decreased functional capacity

Inactive Publication Date: 2005-08-10
埃里斯医疗公司
View PDF5 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In addition, functional capacity begins to decline, quality of life suffers, and frequency of hospitalization increases

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Compositions and methods for treating emphysema
  • Compositions and methods for treating emphysema
  • Compositions and methods for treating emphysema

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 3

[0052] Example 3 describes a variety of surface membranes, and Table 1, which summarizes many of the biophysical characteristics of these surface membranes, demonstrates that similar biophysical behavior can be produced using a variety of unique lipid profiles.

[0053] Table 1

[0054] Composition k 1 k 2 gamma min gamma *

[0055] m 2

[0056] DAPC(0.7)+PG(0.2)

[0057] +DPPC(0.05)+AA(0.05) 6×10 5 6 <0.5 38

[0058] 170

[0059] DAPC(0.7)+DPPC(0.2) 2 <0.5 45

[0060] +AA(0.05)+PA(0.05) 6×10 5

[0061] 170

[0062] DPPC(0.7)+PG(0.2) 10 <0.5 43

[0063]+AA(0.075)+Chol(0.025) 3×10 5

[0064] 170

[0065] DAPC(0.65)+PG(0.15)

[0066] +AA(0.1)+PA(0.08)+ 6×10 5 8 <0.5 51

[0067] 170

[0068] Synthetic SPC(0.02)

[0069] Although the compositions shown here are mixtures comprising almost exclusively lipid components, naturally occurring proteins or synthetic peptides may also be included. Indeed, inclusion of these prot...

Embodiment 1

[0083] Example 1: Tissue-based model of emphysema.

[0084] Collagen and elastic fibers in the alveolar walls are observed in many cases and can be examined in a variety of ways (see e.g. figure 2 ). For example, lung tissue comprising alveoli can be obtained from a healthy animal (including a human patient) or from a human or other animal with enlarged alveoli as a result of a natural or experimentally induced disease process such as emphysema. Tissue can be mechanically stretched as a result of being subjected to forces mimicking the forces experienced by tissue during in vivo respiration (including shallow, normal or deep respiration), and it can be stretched in the presence or absence of pharmaceutical compositions such as known surfactants or in the case of surface films of the invention were stretched to evaluate the ability of those compositions to reduce fiber breakage.

[0085] As mentioned above, as the alveoli enlarge, fiber rupture occurs at tensions close to no...

Embodiment 2

[0087] Example 2: Computer-Based Emphysema Model Showing Decreased Lung Volumes.

[0088] A finite element computer model was used to simulate the lung consisting of a network of tension-supporting fibers equivalent to collagen and elastic fibers in the alveolar walls. Using parameter values ​​representative of human lung physiology, this model identifies foci of concentrated hypertension that tend to distribute along alveolar edges. Under stretching, fibers under high tensile stress (shown in image 3 And marked as fibers 1, 2, 3) were broken, resulting in enlargement of the alveoli and expansion of focal tension concentrations. This process becomes self-propagating as disruption leads to further weakening. The net results were similar to those seen in clinical practice and consistent with observations made after LVRS. Despite initial improvement, rapid decline in lung function occurs after LVRS. The procedure is performed to enhance tissue retraction, but at the same tim...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
surface tensionaaaaaaaaaa
Login to view more

Abstract

The present invention features compositions and methods for treating emphysema by reducing the amount of force the fibers in the lung (e.g., the collagen and elastin fibers in the walls of the alveoli) must bear. More particularly, in one embodiment, the invention features a pharmaceutically acceptable composition comprising a lipid that, when applied to an enlarged alveolus (e.g., an alveolus having a diameter substantially larger than (e.g., 5, 10, 20, 50 or 100 % or more than) the average alveoli in a healthy patient (i.e., a patient with no discernable lung disease), exerts a surface tension within the alveolus that substantially reduces the stress on fibers within the alveolus when inflated by a normal inspiration. The composition can display a gamma* of about 30 to about 70 dynes / cm.

Description

technical field [0001] The present invention describes compositions and methods for treating patients suffering from certain lung diseases, such as emphysema. Background of the invention [0002] Emphysema and asthma and chronic bronchitis represent a syndrome of diseases known as chronic obstructive pulmonary disease (COPD). These three disorders are linked because any of them can cause breathing difficulties, and in most cases they progress over time. However, they differ fundamentally in etiology, pathology, and diagnosis. For example, asthma and chronic bronchitis are airway diseases, whereas emphysema is associated with irreversible and damaging changes in the lung parenchyma distal to the terminal bronchioles. Smoking is a major cause of emphysema; smoke triggers an intrapulmonary inflammatory response associated with activation of both elastase and matrix metalloproteinases (MMPs). These enzymes degrade key proteins that constitute the network structure of lung tis...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/20A61K31/202A61K31/56A61K9/72A61K31/565A61K31/573A61K31/575A61K31/662A61K31/685A61K38/00A61K38/17A61K45/00A61K45/06A61P11/00
CPCA61K45/06A61K31/20A61K31/565A61K38/1709A61K31/685A61P11/00A61K2300/00
Inventor 爱德华德·因杰尼托
Owner 埃里斯医疗公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap